1. Nephrogenic fibrosing dermopathy [NFD/NSF Website];Cowper,2001
2. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?;Grobner;Nephrol Dial Transplant,2006
3. Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging;Marckmann;J Am Soc Nephrol,2006
4. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned;Broome;Am J Radiol,2007
5. Food and Drug Administration Public Health Advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI). Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm. Accessed January 20, 2007.